SCHEMBL5018439

SCHEMBL5018439

CC(C)CCOc1ccc(CNC(=O)[C@H](CCc2ccccc2)NC(=O)[C@@H](N)CC(=O)N(CCN)CCN)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 9/20 0.46
KDM1A O60341 2/20 0.44
PSMB5 P28074 3/20 0.43
PSMB1 P20618 1/20 0.43
PSMB8 P28062 1/20 0.43
PSMB9 P28065 1/20 0.43
PSMB10 P40306 1/20 0.43
PSMB2 P49721 1/20 0.43
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
KLK1 P06870 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5018210 0.92 KLKB1 (0.49) KLKB1PSMB5PSMB1PSMB8PSMB9
SCHEMBL5018480 0.91 KLKB1 (0.54) KLKB1KLK1MEN1KMT2A
SCHEMBL5018333 0.91 KLKB1 (0.45) KLKB1KDM1APSMB5PSMB1PSMB8
SCHEMBL5018322 0.89 ALPL (0.44) KLKB1PSMB5PSMB1PSMB8PSMB9
SCHEMBL5018326 0.86 CTSS (0.43) KLKB1PSMB5PSMB1PSMB8PSMB9
SCHEMBL5018191 0.86 ALDH1A1 (0.47) PSMB5NFKB1NFKB2RELA
SCHEMBL5018306 0.86 NPY1R (0.47) KLKB1PSMB5NFKB1NFKB2RELA
SCHEMBL5018604 0.85 KLKB1 (0.41) KLKB1PSMB5PSMB1PSMB8PSMB9
SCHEMBL5018684 0.85 KLKB1 (0.50) KLKB1PSMB5PSMB1PSMB8PSMB9
SCHEMBL5018262 0.85 KLKB1 (0.50) KLKB1PSMB5PSMB1PSMB8PSMB9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
WO-2010054102-A2 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF MPEX PHARMACEUTICALS, INC. (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152098-A1 POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF ABCB11, ABCB1, SLC47A1 KLKB1 2848/4885KDM1A 4293/4885PSMB5 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.